DURHAM, N.C.--(BUSINESS WIRE)-- BioSkryb, Inc., a developer of genomic amplification technologies, today announced the launch of a research grant program sponsored by the company to accelerate innovation of single-cell genomic studies using its primary template-directed amplification (PTA) technology, now commercially available as the ResolveDNA™ suite of products. The program will support two researchers, each awarded a grant worth up to $20,000, for demonstrating that their research can fuel new discoveries in single-cell genomics and have a positive impact upon improving human health.

Grant applications are now being accepted through January 29th, 2021 and winners will be announced on March 1st, 2021 at The Advances in Genome Biology and Technology (AGBT) 2021 General Meeting. Awardees will receive all materials required to perform a whole genome sequencing workflow from sample-to-analysis for variant detection and characterization from single-cell and ultra-low input samples, including:

• ResolveDNA™ Complete Starter Pack
• Whole-Genome Sequencing of up to eight human cells
• Access to Trailblazer, BioSkryb’s cloud-based bioinformatics platform
• Dedicated technical support

“Our grant program was created to recognize and support researchers who entered the field of genomics because they want to make a transformative discovery that can have a huge impact on understanding human health and treating disease,” said Jay West, Ph.D., CEO and cofounder of BioSkryb. “In advancing such discoveries and achieving meaningful scientific goals, these researchers want to work with best-in-class technologies that are capable of powering the exploration of new genomic frontiers.”

The ResolveDNA suite of products incorporates BioSkryb’s new PTA technology that employs controlled reaction parameters to reproducibly recover >95% of the genomes of single cells and low-input samples with high accuracy and uniformity. The PTA technology was designed to arm researchers with the required breadth, specificity, and sensitivity to define cellular heterogeneity at the most basic building blocks of life – the single cell. PTA can overcome limitations of current whole genome amplification methods and provide a high-quality, scalable, and reliable solution for many single-cell genomic applications, including cancer genomics, cardiology, neurology, immunology, toxicology, bioprocessing, and preimplantation genetic testing.

“I am setting up my own lab, and BioSkryb has been extremely supportive. We can use PTA to detect mutations with high-confidence, sensitivity, and accuracy in single cells,” said Juan Garaycoechea, Group Leader, Hubrecht Institute. “This really opens up a lot of interesting avenues for us, and places us in the right position to discover some very exciting new biology.”

To apply for the grant, researchers must answer three questions regarding the significance of their research, the hypothesis being addressed, and the human condition that will benefit from the studies. For more information about the application process, please visit: https://bioskryb.com/grant/

About BioSkryb

BioSkryb is a venture-backed developer of genomic amplification technologies based in Durham, North Carolina. Its proprietary Primary Template-directed Amplification (PTA) system delivers reproducible, high coverage breadth, and uniformity for various low or ultra-low input sequencing applications. The ResolveDNA product line incorporates BioSkryb’s novel primary template-directed amplification (PTA) technology, which captures more than 95% of the genomes of single cells to provide high-quality, scalable analysis of single-cell genomic heterogeneity. BioSkryb’s products support sequencing library generation produced from limiting samples that have undergone whole genome amplification, resulting in the highest quality genetic analyses available today. For more information, please visit: https://www.bioskryb.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201210005142/en/